Dual inhibition of CDK4/6 and IL-6 pathways as a novel therapeutic approach for triple-negative breast cancer cells

被引：0
|
作者：
Caroland, Kailey
Shi, Changyou
Lo, Hui-Wen
Lin, Jiayuh
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 06期
关键词：
D O I：
10.1158/1538-7445.AM2024-4610
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4610
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Inhibition of CDK4/6 as a novel therapeutic option for neuroblastoma
    Rihani, Ali
    Vandesompele, Jo
    Speleman, Frank
    Van Maerken, Tom
    CANCER CELL INTERNATIONAL, 2015, 15
  • [32] LPM3770277, a Potent Novel CDK4/6 Degrader, Exerts Antitumor Effect Against Triple-Negative Breast Cancer
    Qiu, Jiahao
    Bai, Xinfa
    Zhang, Wenjing
    Ma, Mingxu
    Wang, Wenyan
    Liang, Ye
    Wang, Hongbo
    Tian, Jingwei
    Yu, Pengfei
    FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [33] Bazedoxifene is a novel IL-6/GP130 inhibitor for treating triple-negative breast cancer
    Jilai Tian
    Xiang Chen
    Shengling Fu
    Ruijie Zhang
    Li Pan
    Yang Cao
    Xiaojuan Wu
    Hui Xiao
    Huey-Jen Lin
    Hui-Wen Lo
    Ying Zhang
    Jiayuh Lin
    Breast Cancer Research and Treatment, 2019, 175 : 553 - 566
  • [34] Bazedoxifene is a novel IL-6/GP130 inhibitor for treating triple-negative breast cancer
    Tian, Jilai
    Chen, Xiang
    Fu, Shengling
    Zhang, Ruijie
    Pan, Li
    Cao, Yang
    Wu, Xiaojuan
    Xiao, Hui
    Lin, Huey-Jen
    Lo, Hui-Wen
    Zhang, Ying
    Lin, Jiayuh
    BREAST CANCER RESEARCH AND TREATMENT, 2019, 175 (03) : 553 - 566
  • [35] Differential metabolic response of triple-negative and estrogen receptor-positive breast cancer cells to abemaciclib, a CDK4/6 inhibitor
    Jiang, Jun
    Bao, Xun
    Jiang, Yuanyuan
    Yue, Yang
    Huettemann, Maik
    Li, Jing
    CANCER RESEARCH, 2024, 84 (06)
  • [36] Targeting CDK4/6 pathways and beyond in breast cancer
    Ribnikar, Domen
    Volovat, Simona Ruxandra
    Cardoso, Fatima
    BREAST, 2019, 43 : 8 - 17
  • [37] FSIP1 enhances the therapeutic sensitivity to CDK4/6 inhibitors in triple-negative breast cancer patients by activating the Nanog pathway
    Guanglei Chen
    Lisha Sun
    Xi Gu
    Liping Ai
    Jie Yang
    Zhan Zhang
    Pengjie Hou
    Yining Wang
    Xunyan Ou
    Xiaofan Jiang
    Xinbo Qiao
    Qingtian Ma
    Nan Niu
    Jinqi Xue
    Hao Zhang
    Yongliang Yang
    Caigang Liu
    Science China Life Sciences, 2023, (12) : 2805 - 2817
  • [38] FSIP1 enhances the therapeutic sensitivity to CDK4/6 inhibitors in triple-negative breast cancer patients by activating the Nanog pathway
    Guanglei Chen
    Lisha Sun
    Xi Gu
    Liping Ai
    Jie Yang
    Zhan Zhang
    Pengjie Hou
    Yining Wang
    Xunyan Ou
    Xiaofan Jiang
    Xinbo Qiao
    Qingtian Ma
    Nan Niu
    Jinqi Xue
    Hao Zhang
    Yongliang Yang
    Caigang Liu
    Science China(Life Sciences), 2023, 66 (12) : 2805 - 2817
  • [39] FSIP1 enhances the therapeutic sensitivity to CDK4/6 inhibitors in triple-negative breast cancer patients by activating the Nanog pathway
    Guanglei Chen
    Lisha Sun
    Xi Gu
    Liping Ai
    Jie Yang
    Zhan Zhang
    Pengjie Hou
    Yining Wang
    Xunyan Ou
    Xiaofan Jiang
    Xinbo Qiao
    Qingtian Ma
    Nan Niu
    Jinqi Xue
    Hao Zhang
    Yongliang Yang
    Caigang Liu
    Science China Life Sciences, 2023, 66 : 2805 - 2817
  • [40] FSIP1 enhances the therapeutic sensitivity to CDK4/6 inhibitors in triple-negative breast cancer patients by activating the Nanog pathway
    Chen, Guanglei
    Sun, Lisha
    Gu, Xi
    Ai, Liping
    Yang, Jie
    Zhang, Zhan
    Hou, Pengjie
    Wang, Yining
    Ou, Xunyan
    Jiang, Xiaofan
    Qiao, Xinbo
    Ma, Qingtian
    Niu, Nan
    Xue, Jinqi
    Zhang, Hao
    Yang, Yongliang
    Liu, Caigang
    SCIENCE CHINA-LIFE SCIENCES, 2023, 66 (12) : 2805 - 2817
12345